Oral Administration of Fucoidan Can Exert Anti-Allergic Activity after Allergen Sensitization by Enhancement of Galectin-9 Secretion in Blood
Oral Administration of Fucoidan Can Exert Anti-Allergic Activity after Allergen Sensitization by Enhancement of Galectin-9 Secretion in Blood
复制标题
DOI：
10.3390/biom10020258
复制
发表时间：
2020-02-01
期刊：
影响因子：
5.5
通讯作者：
Sakane, Iwao
中科院分区：
文献类型：
--
作者：
Mizuno, Masashi;Sakaguchi, Kana;Sakane, Iwao
先前的研究表明，岩藻依聚糖通过上调血液中的半乳糖凝集素-9来抑制肥大细胞脱粒。本研究采用卵白蛋白（OVA）致敏小鼠（BALB/c，雌性，5周龄）和肥大细胞系（RBL-2 H3细胞），探讨其作用机制。用OVA/Al（OH）（3）致敏后口服岩藻依聚糖可抑制肥大细胞活化引起的直肠温度降低。褐藻糖胶仅在结肠上皮细胞中增加半乳糖凝集素-9 mRNA的表达。这些结果表明，岩藻聚糖可以通过诱导结肠上皮细胞产生半乳凝素-9来抑制致敏小鼠的过敏症状。此外，为了检查半乳糖凝集素9对肥大细胞脱粒的影响，用重组半乳糖凝集素-9直接处理RBL-2 H3细胞系。如预期的，半乳糖凝集素-9抑制与IgE预结合的RBL-2 H3细胞的脱粒。此外，通过添加半乳糖凝集素-9降低了RBL-2 H3细胞上IgE的残留量。研究表明，即使IgE已经与肥大细胞结合，半乳凝素-9也可以去除IgE，并抑制抗原诱导的肥大细胞脱颗粒。这项研究表明，褐藻糖胶可能成为一种有效的治疗剂，为患者已经发展为I型过敏性疾病。
A previous study revealed that fucoidan inhibited mast cell degranulation through the upregulation of galectin-9 in blood. The purpose of this study is to elucidate its mechanism using ovalbumin (OVA) induced anaphylaxis model mice (BALB/c, Female, 5-week-old) and mast cell line (RBL-2H3 cells). Oral administration of fucoidan after sensitization with OVA/Al(OH)(3) inhibited reduction of rectal temperature induced by activation of mast cells. Fucoidan increased galectin-9 mRNA expression only in colonic epithelial cells. These results suggested that fucoidan could suppress the allergic symptoms in sensitized mice by inducing galectin-9 production from colonic epithelial cells. In addition, to check the influence of galectin 9 on the degranulation of mast cells, RBL-2H3 cell lines were treated directly with recombinant galectin-9. As expected, galectin-9 inhibited degranulation of RBL-2H3 cells pre-bound with IgE. Moreover, the residual amounts of IgE on RBL-2H3 cells were decreased by an addition of galectin-9. It was demonstrated that galectin-9 could remove IgE even if IgE was already bound to mast cells and suppress the mast cells degranulation induced by antigen. This study shows that fucoidan might become an effective therapeutic agent for patients already developed type I allergic diseases.